Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Protagonist Therapeutics (PTGX) over the last 9 years, with Q1 2025 value amounting to -$5000.0.

  • Protagonist Therapeutics' Gains from Investment Securities changed N/A to -$5000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $30.2 million, marking a year-over-year increase of 539799.64%. This contributed to the annual value of $7.8 million for FY2024, which is 132.4% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Gains from Investment Securities stood at -$5000.0 for Q1 2025.
  • In the past 5 years, Protagonist Therapeutics' Gains from Investment Securities registered a high of $30.2 million during Q4 2024, and its lowest value of -$5000.0 during Q1 2025.
  • For the 5-year period, Protagonist Therapeutics' Gains from Investment Securities averaged around $8.2 million, with its median value being $6.6 million (2022).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 93791.69% in 2021, then soared by 587.55% in 2022.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Gains from Investment Securities stood at $5.9 million in 2021, then rose by 9.35% to $6.4 million in 2022, then grew by 22.99% to $7.9 million in 2023, then skyrocketed by 281.08% to $30.2 million in 2024, then tumbled by 100.02% to -$5000.0 in 2025.
  • Its Gains from Investment Securities was -$5000.0 in Q1 2025, compared to $30.2 million in Q4 2024 and $7.9 million in Q4 2023.